###begin article-title 0
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
CHOP 5'UTR-c.279T>C and +nt30C>T variants are not associated with overweight condition or with tumors/cancer in Italians - a case-control study
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 114 124 114 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HNF1-beta </italic>
###xml 128 134 128 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JAZF1 </italic>
###xml 215 220 215 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 331 336 331 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 396 401 396 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 522 527 522 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 320 324 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 368 373 <span type="species:ncbi:9606">human</span>
Type 2 diabetes (T2D) is associated with obesity and has been shown recently to be associated with tumors/cancer. HNF1-beta and JAZF1 genes are associated with T2D and prostate cancer. We have previously shown that CHOP 5'UTR-c.279T>C and +nt30C>T haplotype variants contribute to T2D. CHOP deficiency causes obesity in mice, thus CHOP gene variants may contribute to human obesity. Furthermore, CHOP mediates apoptosis and is implicated in cancer pathogenesis. Hence, we aimed at identifying any potential association of CHOP 5'UTR-c.279T>C and +nt30C>T genotypes and corresponding haplotypes with overweight condition/pre-obesity and tumors/cancer in an Italian dataset.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
We recruited from Italy 45 overweight subjects (body mass index (BMI) >/= 25) and 44 control subjects (BMI < 25) as well as 54 cases with at least one cancer or at least one tumor and 43 control subjects without tumors/cancer from the general population. We excluded allelic departure from Hardy-Weinberg equilibrium in cases and control subjects, separately.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
We assessed the power to detect risk odds ratios by association tests in our datasets. We tested the hypothesis of association of CHOP 5'UTR-c.279T>C and +nt30C>T genotypes and haplotypes with tumors/cancer and, separately, with overweight condition. Both associations were not significant.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 225 230 225 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
From our study, we may conclude that CHOP 5'UTR-c.279T>C and +nt30C>T genotypes and corresponding haplotypes are not associated with tumors/cancer and pre-obesity. However, more studies are warranted to establish the role of CHOP variants in tumor/cancer predisposition and in overweight condition.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 115 116 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 223 234 223 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HNF-1 beta </italic>
###xml 238 243 238 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JAZF1</italic>
###xml 288 289 288 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 610 615 610 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 699 704 699 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 825 826 825 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 870 871 870 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 879 884 879 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 936 937 936 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 938 940 938 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 958 960 958 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1041 1043 1041 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
Type 2 diabetes (T2D) is associated with obesity. There is increasing evidence that T2D is associated with tumors [1] and cancers of the pancreas [2], prostate, breast, colon, endometrium, and liver [3]. T2D genes, such as HNF-1 beta and JAZF1, have been associated with prostate cancer [4-6]. Thus, T2D candidate genes may not only be obesity predisposing genes, but also tumor/cancer risk genes. CHOP mediates apoptosis and regulates mitochondrial gene expression, thus it may be implicated in beta cell inability to replicate as well as in insulin secretion defects. Following up on a linkage signal in the CHOP region of chromosome 12q13.1 in Italian T2D families, we have previously shown that CHOP 5'UTR-c.279T>C and +nt30C>T haplotype variants are associated with early-onset T2D under a recessive and additive model [7]. In addition, CHOP inhibits adipogenesis [8], thus CHOP gene variants may contribute to insulin resistance [9,10] and/or obesity [11]. Since CHOP is regulating programmed cell death in response to stress stimuli [12], it is implicated in tumor/cancer development.
###end p 11
###begin p 12
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 250 259 250 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EWS-CHOP </italic>
###xml 263 275 263 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLS/FUS-CHOP</italic>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 372 377 372 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 67 72 <span type="species:ncbi:9606">human</span>
CHOP is involved in the pathogenesis of myxoid liposarcoma, a rare human tumor in which a reciprocal chromosomal translocation creates a fusion protein consisting of CHOP and TLS, a potent oncoprotein [13]. Other tumor-specific fusion genes, such as EWS-CHOP and TLS/FUS-CHOP, have been detected in solid tumors [14] and liposarcomas [15-17]. Another rearrangement of the CHOP gene has been reported in myxoid liposarcoma [18].
###end p 12
###begin p 13
###xml 60 65 60 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 166 167 166 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
Our aim was to find whether there is any association of the CHOP 5'UTR-c.279T>C and +nt30C>T genotypes and corresponding haplotypes (the latter contributing to T2D) [7] with body mass index (BMI) >/= 25 (hereby defined as overweight condition/pre-obesity) and/or with tumors/cancer in an Italian dataset.
###end p 13
###begin title 14
Methods
###end title 14
###begin p 15
###xml 512 517 510 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
We recruited from the general population in Italy 45 subjects with BMI >/= 25 and 44 control subjects with BMI < 25 and 54 subjects with at least one cancer or at least one tumor and 43 control subjects with no history of tumor or cancer. We obtained the written informed consent from each subject and the approval from the Institutional Review Board accordingly to Helsinki Declaration guidelines. DNA samples were directly sequenced by PCR and an automated fluorescence sequencer with specific primers for the CHOP 5'UTR-c.279T>C and +nt30C>T genotypes.
###end p 15
###begin p 16
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
We calculated via 70% power and type 1 error probability of 0.05, detectable odds ratios for genotype association tests in our two datasets, using the prevalence of 31.3% for overweight condition [19] and the prevalence of 2.7% for tumors/cancer in the Italian population [20].
###end p 16
###begin p 17
Via Chi-Square test statistics, we tested the alleles for departure from Hardy-Weinberg equilibrium (HWE) in our two datasets in cases and control subject groups, separately.
###end p 17
###begin p 18
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
Via the Mantel-Haenszel algorithm, we tested the CHOP 5'UTR-c.279T>C and +nt30C>T genotypes for association with BMI >/= 25 and with tumors/cancer.
###end p 18
###begin p 19
###xml 194 196 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
In addition, we performed model free and parametric haplotype associations tests (dominant, recessive and additive models) for BMI >/= 25 and for tumors/cancer, independently (EHPLUS software) [21].
###end p 19
###begin title 20
Results
###end title 20
###begin p 21
Risk odds ratios of 0.248/2.943 for genotypes association tests were detectable in the pre-obesity dataset. Risk odds ratios of 8.210 for genotype association tests were detectable in the tumors/cancer dataset.
###end p 21
###begin p 22
All alleles tested in each group of the two datasets of BMI >/= 25 and of tumors/cancer were not in departure from HWE.
###end p 22
###begin p 23
###xml 80 85 80 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 154 155 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 203 204 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
We did not identify in our dataset any significant and valid association of the CHOP 5'UTR-c.279T>C and +nt30C>T genotype variants with BMI >/= 25 (Table 1) as well as with tumors/cancer patients (Table 2).
###end p 23
###begin p 24
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
CHOP 5'UTR-c.279T>C and +nt30C>T genotype association with overweight condition (BMI >/= 25).
###end p 24
###begin p 25
###xml 1 3 1 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
X2 = Chi-Square, 2-t P = 2-tailed p-value, OR = odds ratio,
###end p 25
###begin p 26
C.I. = confidence interval
###end p 26
###begin p 27
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
CHOP 5'UTR-c.279T>C and +nt30C>T genotype association with tumors/cancer.
###end p 27
###begin p 28
###xml 1 3 1 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
X2 = Chi-Square, 2-t P = 2-tailed p-value, OR = odds ratio,
###end p 28
###begin p 29
C.I. = confidence interval
###end p 29
###begin p 30
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
The parametric and non-parametric CHOP 5'UTR-c.279T>C and +nt30C>T haplotype association tests with BMI >/= 25 as well as with tumors/cancer were also not significant (data not shown).
###end p 30
###begin title 31
Discussion
###end title 31
###begin p 32
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 194 199 194 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 269 274 269 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 333 342 333 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EWS-CHOP </italic>
###xml 346 358 346 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLS/FUS-CHOP</italic>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
CHOP gene encodes a C/EBP (CCAAT/enhancer binding protein family)-homologous nuclear protein that acts as dominant-negative inhibitor of gene transcription through dimerization with C/EBP [22]. CHOP is implicated in programmed cell death [12]. Several studies reported CHOP gene rearrangement and/or fusion with other genes (such as EWS-CHOP and TLS/FUS-CHOP) in tumors/cancer [13,18].
###end p 32
###begin p 33
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 257 262 257 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 343 344 343 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
Cellular and endoplasmic reticulum (ER) stress, occurring in response to toxic and metabolic insult, is a powerful inducer of CHOP [12]. ER stress down-regulates insulin receptor signaling and triggers insulin resistance [9]. Furthermore, insulin increases CHOP expression in adipocyte cells [23], and CHOP inhibits adipocyte differentiation [8]. Thus, CHOP deficiency may contribute to obesity [11].
###end p 33
###begin p 34
###xml 39 41 39 41 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 177 182 177 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 317 318 317 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 348 353 348 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 511 522 511 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HNF-1 beta </italic>
###xml 526 531 526 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JAZF1</italic>
###xml 584 585 584 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 586 587 586 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 630 641 630 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HNF-1 beta </italic>
###xml 676 677 676 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 692 698 692 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JAZF1 </italic>
###xml 776 777 776 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 778 779 778 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
Glucotoxicity induces cellular stress [24], which activates CHOP [12]. Thus, hyperglycemia may cause CHOP-mediated beta-cell apoptosis and may contribute to T2D. Interestingly, CHOP 5'UTR-c.279T>C and +nt30C>T haplotype variants are significantly associated with early-onset T2D under a recessive and additive model [7]. For all the above reasons, CHOP is not only a T2D gene, but it is also an obesity candidate gene as well as a gene potentially predisposing to tumors and/or cancer. Other T2D genes, such as HNF-1 beta and JAZF1, have already been associated with prostate cancer [4-6]. Of note, while the prostate cancer risk HNF-1 beta variant decreases the risk of T2D [4], variants of JAZF1 gene are associated with both increased risk for T2D and for prostate cancer [5,6].
###end p 34
###begin p 35
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 182 187 182 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
###xml 204 209 <span type="species:ncbi:9606">human</span>
However, no study has up to date investigated the susceptibility role of CHOP common variants in pre-obese and tumor/cancer patients. This is the first association study focusing on CHOP gene variants in human genomic DNA samples of overweight subjects and tumor/cancer cases.
###end p 35
###begin p 36
###xml 58 63 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 171 176 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 397 402 397 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
In our study, we did not identify any association between CHOP 5'UTR-c.279T>C and +nt30C>T genotype and haplotype variants with pre-obesity and with tumors/cancer. If the CHOP gene variants tested were to contribute to overweight condition and/or tumors/cancer with a modest size effect, our datasets are too small to detect such effects. However, we could at least exclude in the current study a CHOP 5'UTR-c.279T>C and +nt30C>T variant risk effect of about 3 for pre-obesity and of about 8 for tumors/cancer.
###end p 36
###begin title 37
Conclusion
###end title 37
###begin p 38
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 274 279 274 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHOP </italic>
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
In summary, we conclude that CHOP 5'UTR-c.279T>C and +nt30C>T variants, both at genotype and at haplotype level, are not contributing to the overweight condition and tumors/cancer in our dataset. However, other studies are warranted to further exclude the role of any other CHOP variants in obesity and in tumor/cancer predisposition. Since obesity is a preventable associated factor in several tumors/cancer [25] and in other co-morbidities [26], and, since tumors and cancer may be prevented and/or diagnosed at an earlier stage, genetic studies to identity overweight risk predisposition as well as tumors/cancer risk susceptibility should be further performed to guide disease prediction and prevention.
###end p 38
###begin title 39
Competing interests
###end title 39
###begin p 40
The authors declare that they have no competing interests.
###end p 40
###begin title 41
Authors' contributions
###end title 41
###begin p 42
CG participated in study design, DNA amplification, sequence reading, project coordination and manuscript drafting and revising. RM carried out the statistical analysis, reference collection, and manuscript drafting. NP and LP executed PCR set up, DNA amplification and sequence reading.
###end p 42
###begin p 43
All authors have read and approved the manuscript.
###end p 43
###begin title 44
Acknowledgements
###end title 44
###begin p 45
Special thanks go to the Molecular Biology staff of Bios Biotech Multi-Diagnostic Health Center (Rome, Italy), which has provided technical as well as financial support for this study.
###end p 45
###begin p 46
###xml 367 374 <span type="species:ncbi:4097">Tobacco</span>
This study was made possible by the Penn State University Physician-Scientist Stimulus Award and by the Dean's Pilot and Feasibility Grant, number D1BTH06321-01 from the Office for the Advancement of Tele health (OAT), Health Resources and Services Administration, DHHS. This project is funded, in part, under a grant from the Pennsylvania Department of Health using Tobacco Settlement Funds. The Department specifically disclaims responsibility for any analyses, interpretations or conclusions.
###end p 46
###begin article-title 47
Diabetes and oral tumors in Hungary: epidemiological correlations
###end article-title 47
###begin article-title 48
Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies
###end article-title 48
###begin article-title 49
The relation of type 2 diabetes and cancer
###end article-title 49
###begin article-title 50
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes
###end article-title 50
###begin article-title 51
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes
###end article-title 51
###begin article-title 52
Multiple loci identified in a genome-wide association study of prostate cancer
###end article-title 52
###begin article-title 53
CHOP T/C and C/T haplotypes contribute to early-onset type 2 diabetes in Italians
###end article-title 53
###begin article-title 54
Inhibition of adipogenesis by the stress-induced protein CHOP (Gadd153)
###end article-title 54
###begin article-title 55
Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes
###end article-title 55
###begin article-title 56
Involvement of endoplasmic reticulum stress in insulin resistance and diabetes
###end article-title 56
###begin article-title 57
###xml 15 19 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Chop-deficient mice showed increased adiposity but no glucose intolerance
###end article-title 57
###begin article-title 58
CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum
###end article-title 58
###begin article-title 59
###xml 49 54 <span type="species:ncbi:9606">human</span>
Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma
###end article-title 59
###begin article-title 60
Fusion genes in solid tumors
###end article-title 60
###begin article-title 61
Specificity of TLS-CHOP rearrangement for classic myxoid/round cell liposarcoma: absence in predominantly myxoid well-differentiated liposarcomas
###end article-title 61
###begin article-title 62
A novel type of EWS-CHOP fusion gene in two cases of myxoid liposarcoma
###end article-title 62
###begin article-title 63
###xml 79 84 <span type="species:ncbi:9606">human</span>
Chimeric TLS/FUS-CHOP gene expression and the heterogeneity of its junction in human myxoid and round cell liposarcoma
###end article-title 63
###begin article-title 64
Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11)
###end article-title 64
###begin article-title 65
Overweight and obesity in Italian adults and an overview of trends since 1983
###end article-title 65
###begin article-title 66
Cancer prevalence in Italian cancer registry areas: the ITAPREVAL study. ITAPREVAL Working Group
###end article-title 66
###begin article-title 67
Model-free analysis and permutation tests for allelic associations
###end article-title 67
###begin article-title 68
CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription
###end article-title 68
###begin article-title 69
Insulin induces chaperone and CHOP gene expressions in adipocytes
###end article-title 69
###begin article-title 70
Glucolipotoxicity: fuel excess and beta-cell dysfunction
###end article-title 70
###begin article-title 71
###xml 38 46 <span type="species:ncbi:9606">patients</span>
Prevalence of cancer in Italian obese patients referred for bariatric surgery
###end article-title 71
###begin article-title 72
Comorbidities of overweight and obesity: current evidence and research issues
###end article-title 72

